Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.00 USD
−75.52 M USD
0.00 USD
19.58 M
About Aerovate Therapeutics, Inc.
Sector
Industry
CEO
Timothy P. Noyes
Website
Headquarters
Waltham
Founded
2018
FIGI
BBG00WGHZFH4
Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was founded by Benjamin T. Dake on July 27, 2018 and is headquartered in Waltham, MA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of AVTE is 2.64 USD — it has decreased by −1.49% in the past 24 hours. Watch Aerovate Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Aerovate Therapeutics, Inc. stocks are traded under the ticker AVTE.
AVTE stock has fallen by −1.12% compared to the previous week, the month change is a 24.53% rise, over the last year Aerovate Therapeutics, Inc. has showed a −83.50% decrease.
We've gathered analysts' opinions on Aerovate Therapeutics, Inc. future price: according to them, AVTE price has a max estimate of 3.00 USD and a min estimate of 2.00 USD. Watch AVTE chart and read a more detailed Aerovate Therapeutics, Inc. stock forecast: see what analysts think of Aerovate Therapeutics, Inc. and suggest that you do with its stocks.
AVTE reached its all-time high on Apr 1, 2024 with the price of 32.42 USD, and its all-time low was 1.25 USD and was reached on Jun 20, 2024. View more price dynamics on AVTE chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
AVTE stock is 3.05% volatile and has beta coefficient of 1.12. Track Aerovate Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Aerovate Therapeutics, Inc. there?
Today Aerovate Therapeutics, Inc. has the market capitalization of 76.23 M, it has increased by 3.16% over the last week.
Yes, you can track Aerovate Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Aerovate Therapeutics, Inc. is going to release the next earnings report on Mar 26, 2025. Keep track of upcoming events with our Earnings Calendar.
AVTE net income for the last quarter is −16.24 M USD, while the quarter before that showed −24.77 M USD of net income which accounts for 34.46% change. Track more Aerovate Therapeutics, Inc. financial stats to get the full picture.
No, AVTE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 29, 2024, the company has 51.00 employees. See our rating of the largest employees — is Aerovate Therapeutics, Inc. on this list?
Like other stocks, AVTE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Aerovate Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Aerovate Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Aerovate Therapeutics, Inc. stock shows the sell signal. See more of Aerovate Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.